Acute evaluation and management of ischemic stroke-1

Email Comment bookmark
Font : A-A+

Treatment of patients not eligible for thrombolysis

The use of subcutaneous heparin was evaluated in the International Stroke Trial. In this unblinded study, heparin was associated with a reduced incidence of recurrent ischemic strokes within 14 days (2.9 versus 3.8 percent), but there was no significant improvement in outcome at six months and there was a higher risk of intracranial bleeding.

At present there is inadequate data to support the use of subcutaneous or low molecule weight heparin at this time.

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

CME Lessons

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor